NRXP · Nrx Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07M | - | $242.0K | - | $0 | - | - | - | - | - |
| Cost of Revenue | $631.0K | - | $97.0K | - | - | - | - | - | - | - |
| Gross Profit | $437.0K | - | $145.0K | - | - | - | - | - | - | - |
| R&D | $1.31M | - | $1.43M | $987.0K | $1.75M | - | - | $3.31M | $3.87M | $3.65M |
| SG&A | $2.94M | - | $2.41M | $2.74M | $4.25M | - | - | $2.49M | $4.07M | $5.79M |
| Total Operating Expenses | $3.85M | - | $3.02M | $3.73M | $6.00M | - | - | $5.81M | $8.19M | $9.44M |
| D&A | $63.0K | - | $26.0K | - | $1.0K | - | - | - | - | $1.0K |
| Operating Income | ($4.74M) | - | ($4.02M) | ($3.73M) | ($6.00M) | - | - | ($5.81M) | ($8.19M) | ($9.44M) |
| Interest Expense | $0 | - | $0 | $0 | $230.0K | - | - | $40.0K | - | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - | - | - |
| Net Income | ($1.43M) | - | ($5.89M) | ($17.58M) | ($6.53M) | - | - | ($6.06M) | ($8.72M) | ($11.04M) |
| EPS - Basic | ($0.04) | - | ($0.27) | ($0.98) | ($0.74) | - | - | ($0.70) | ($1.20) | ($1.60) |
| EPS - Diluted | - | - | - | - | ($0.74) | - | - | ($0.70) | ($1.20) | ($1.60) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.71M | $7.80M | $7.18M | $2.91M | $5.55M | $1.44M | $4.59M | $8.90M | $14.97M | $16.51M |
| Accounts Receivable | $181.0K | $161.0K | $0 | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.40M | $4.27M | $4.26M | $3.63M | $4.31M | $4.13M | $4.63M | $3.63M | $2.21M | $3.78M |
| Current Assets | $7.36M | $8.89M | $11.95M | $4.59M | $7.26M | $3.30M | $6.88M | $13.09M | $19.79M | $21.76M |
| Total Assets | $11.90M | $12.96M | $15.00M | $4.84M | $7.59M | $3.65M | $7.32M | $13.11M | $19.81M | $21.78M |
| Current Liabilities | $25.18M | $28.58M | $40.59M | $40.45M | $32.75M | $21.86M | $19.05M | $19.33M | $22.62M | $22.06M |
| Long-term Debt | - | - | - | - | - | - | $9.16M | $2.82M | $12.69M | $12.19M |
| Total Liabilities | $25.72M | $28.89M | $40.75M | $40.45M | $32.75M | $26.87M | $19.05M | $19.33M | $22.62M | $22.06M |
| Stockholders' Equity | ($13.82M) | ($15.94M) | ($25.75M) | ($35.62M) | ($25.16M) | ($23.22M) | ($11.73M) | ($6.22M) | ($2.81M) | ($284.0K) |
| Retained Earnings | ($308.32M) | ($306.89M) | ($307.26M) | ($301.37M) | ($283.79M) | ($278.27M) | ($253.15M) | ($248.81M) | ($242.75M) | ($234.04M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.29M) | - | - | - | ($3.67M) | - | - | - | - | ($6.09M) |
| Investing Cash Flow | ($213.0K) | - | - | - | $0 | - | - | - | - | ($4.0K) |
| Financing Cash Flow | $3.42M | - | - | - | $395.0K | - | - | - | - | $2.54M |
| CapEx | - | - | - | - | $0 | - | - | - | - | $4.0K |
| Free Cash Flow | - | - | - | - | ($3.67M) | - | - | - | - | ($6.09M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 40.9% | - | 59.9% | - | - | - | - | - | - | - |
| Operating margin | -444.0% | - | -1662.8% | - | - | - | - | - | - | - |
| EBITDA margin | -438.1% | - | -1652.1% | - | - | - | - | - | - | - |
| Net margin | -133.9% | - | -2433.9% | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.56 | - | - | - | - | 0.55 |
| R&D / Revenue | 122.6% | - | 590.5% | - | - | - | - | - | - | - |
| SG&A / Revenue | 275.6% | - | 995.5% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.0% | - | -39.3% | -363.4% | -86.0% | - | - | -46.2% | -44.0% | -50.7% |
| Return on equity | 10.4% | - | 22.9% | 49.4% | 25.9% | - | - | 97.5% | 310.4% | 3887.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.29 | 0.31 | 0.29 | 0.11 | 0.22 | 0.15 | 0.36 | 0.68 | 0.87 | 0.99 |
| Quick ratio | 0.29 | 0.31 | 0.29 | 0.11 | 0.22 | 0.15 | 0.36 | 0.68 | 0.87 | 0.99 |
| Cash ratio | 0.27 | 0.27 | 0.18 | 0.07 | 0.17 | 0.07 | 0.24 | 0.46 | 0.66 | 0.75 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | -0.78 | -0.45 | -4.52 | -42.92 |
| Debt / Assets | - | - | - | - | - | - | 1.25 | 0.22 | 0.64 | 0.56 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -26.1x | - | - | -145.2x | - | - |
| Equity multiplier | -0.86 | -0.81 | -0.58 | -0.14 | -0.30 | -0.16 | -0.62 | -2.11 | -7.05 | -76.69 |
| Liabilities / Assets | 2.16 | 2.23 | 2.72 | 8.36 | 4.32 | 7.36 | 2.60 | 1.47 | 1.14 | 1.01 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.02 | - | 0.00 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 62d | - | 0d | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 2545d | - | 16019d | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 30.7% | 54.4% | 36.4% | - | - | 36.5% | 14.7% | 39.9% |
| Net income growth (YoY) | - | - | 2.8% | -101.7% | 40.9% | - | - | 33.3% | -24.8% | 17.9% |
| EPS growth (YoY) | - | - | - | - | 53.8% | - | - | -400.0% | -990.9% | -700.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 39.8% | - | - | - | - | 41.3% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 31.4% | -314.3% | -1168.3% | -8759.5% | -97.9% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$1.23M totalTherapy$854.0K · 69.7%
Procedures$371.0K · 30.3%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NRX Pharmaceuticals against the 5 most active filers in the same SIC group.